ArticleInternational ophthalmology2025
Performance of a novel multimodal large language model in ınterpreting meibomian glands quantitatively and qualitatively.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the performance of a multimodal large language model (LLM), Claude 3.5 Sonnet, in interpreting meibography images for Meibomian gland dropout grading and morphological abnormality detection.
methodsA total of 228 meibography images were analyzed by the same researcher and an assessment was performed in terms of gland drop out ratio and morphological abnormalities. Meibomian gland loss was graded from 0 (no loss) to 3 (> 2/3 loss of total gland area). One-hundred and sixty images, comprising 40 images per grade, were included. Claude 3.5 Sonnet, a multimodel LLM, developed by Anthropic (California, United States) was utilized to investigate its performance in evaluating meibography images.
resultsClaude 3.5 Sonnet showed high performance in grading Meibomian gland dropout, correctly scoring 97.5%, 92.5%, 95%, and 85% of images in Grades 0, 1, 2, and 3, respectively. In addition, Claude 3.5 Sonnet showed remarkable performance in detecting morphological abnormalities, including heterogeneous lumen diameters, lumen tortuosity, shortened lumen length, and hyperreflective gland residues. The model detected all of the 48 manually identified morphological abnormalities accurately. In 12 images, initially classified as morphologically normal by the manual assessment, the model reported additional subtle abnormalities.
conclusionClaude 3.5 Sonnet showed promising results in interpreting meibography images, detecting morphological abnormalities and discriminating normal Meibomian glands from abnormal. Claude 3.5 Sonnet might be useful in serving as a complementary educational tool in ophthalmology clinics. The model's ability to perform detailed morphological evaluations and respond to further questions provides a tailored learning experience for young ophthalmic clinicians.
Indexed as
Identifiers
40437329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.